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2Abstract
Introduction: Certain ECG abnormalities are associated with ischemic stroke (IS), especially
cardioembolic subtype. Besides atrial fibrillation, markers of left ventricular hypertrophy (LVH) or
atrial pathology also reflect elevated risk. We studied the association of ECG markers with IS in
young adults.
Methods: We performed a case-control study including 567 consecutive IS patients aged 15 to 49
years (inclusion period 1994-2007) and one or two age- and sex-matched control subjects enrolled
during 1978 to 1980 (n=1033), and investigated also the stroke etiologic subgroups. We studied
ECGs of all participants for markers of atrial abnormality, i.e. P-terminal force (PTF) on lead V1,
interatrial blocks (IAB; P-wave duration ≥110 ms), and LVH. Conditional logistic regression
analyses were used.
Results: IAB (hazard ratio [HR] 1.57, 95% confidence interval [CI] 1.16-2.13) and PTF combined
with LVH (HR 6.83, 95% CI 1.65-28.31), were independently associated with IS. LVH, abnormal
P-wave (HR 6.87, 95% CI 1.97-135.29), PTF, IAB, and combinations of these P-wave
abnormalities with LVH – were associated with cardioembolic subtype. Abnormal P-wave and IAB
were associated with cryptogenic stroke subtype. In unadjusted analysis, LVH was associated with
small-vessel disease subtype.
Conclusions: P-wave abnormalities on ECG were associated with cardioembolic but also with
cryptogenic subtype of IS.
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Key messages:
1. ECG patterns associated with atrial pathology are markers of increased risk of ischemic stroke in
young adults.
2. The ECG markers reflecting atrial pathology were seen in patients with cardioembolic and
cryptogenic subtypes of ischemic stroke.
4Introduction
Atrial fibrillation (AF) is a well-known risk factor for ischemic stroke (IS), but apart from AF,
certain other electrocardiographic (ECG) patterns have also been linked to an elevated risk of stroke
(1-3). These associations are mainly due to cardiac abnormalities, and hence intuitively such ECG
findings should be associated with cardioembolic stroke subtype. In fact, a prolonged P-wave was
associated with cardioembolic stroke in one study (4). Also, a theory on fibrous atrial cardiopathy
has emerged, proposing that unhealthy atrial substrate—regardless of the presence of AF— may
predispose to thrombus formation in the left atrial appendage and left atrium hence increasing the
risk of cardioembolism (5,6). In the general population, left ventricular hypertrophy (LVH) on ECG
has been linked to an increased risk for IS (7).
In young population, however, few studies exist on the association between ECG abnormalities and
IS. In a population of young adults with IS, we have earlier demonstrated that P-terminal force (PTF)
was associated with the subtype of cardioembolism from a high-risk source (8).
One key feature differentiating young patients with IS from older patients is the higher frequency of
cryptogenic strokes, i.e. strokes with undetermined etiology (9). In the case of recently proposed
clinical construct—embolic strokes of undetermined source (ESUS) — clinical and radiological
findings point towards embolism, but the embolic source cannot be identified (10). Based on
preliminary analyses, majority of the cryptogenic strokes at younger ages may fulfill the ESUS
criteria (11).
The secondary prevention of cardioembolic strokes differs markedly from other stroke etiologies.
Thus, it would be of great importance to identify these patients who would be likely to benefit from
thorough examinations to reveal a source of embolism. Therefore, we performed a matched case-
5control study on the association of ECG markers of atrial pathology with early-onset IS.
Furthermore, we aimed to study these associations in stroke etiologic subgroups, with particular
interest in cardioembolism from high-risk sources and ESUS. As the markers of atrial pathology are
relatively common in presumably healthy populations, we also studied whether combining LVH
with these atrial markers would increase their association with IS (12).
6Methods
The stroke cases came from the Helsinki Young Stroke Registry (HYSR), consisting of 1008
consecutive patients with first-ever IS at age of 15 to 49, enrolled during the period between 1994
and 2007 (13). The control subjects were obtained from the 7217 participants of the Mini-Finland
Health Survey enrolled during the period from 1978 to 1980 and representing the Finnish
population 30 years old and over (14). For the present study, we selected 1067 municipality-, age-
and sex matched controls from those free from IS. One or two controls were selected for each
HYSR patient. Municipality was matched by restriction firstly to Helsinki (65%), secondly to Turku
(20%) and thirdly to other municipalities in the Southern part of Finland. Sex and age were selected
by individual matching, age using nearest available matching. Age was considered matched when it
was +/-5 years the age of the patient, therefore patients younger than 25 years were ruled out due to
lack of control subjects. Besides the matching, the following confounding factors were considered
by modeling: systolic blood pressure, diastolic blood pressure, HDL cholesterol, obesity (BMI ≥ 30
kg/m2), diabetes, coronary artery disease and cigarette smoking. More detailed definitions of these
factors are described in supplementary Table s1.
The ECG of stroke patients was obtained at least 1 day after, and always within 14 days of their
stroke. Because our study focused on P-wave parameters, only patients and controls in sinus rhythm
were selected; the Mini-Finland Health Survey persons with their studied ECG in AF were excluded
from the present study.  Also persons with incomplete data on the considered clinical parameters
were excluded. Only the case-control sets containing complete data of the aforementioned factors in
the case and one control were included. A total of 567 stroke patients (63.5% male) and 1033
matched controls had complete data on all the studied variables, and were in sinus rhythm, and were
included in the present study. CHADS2 and CHA2DS2-VASc scores were calculated for the stroke
patients, according to established criteria (15,16).
7The study was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa
(no. 73/13/03/00/11) and by the National Institute of Health and Welfare (THL).The Mini-Finland
Health Survey preceded the current legislation on ethics in medical research. All participants were
fully informed about the study, they participated in the study voluntarily and the use of the
information for medical research was explained to them. Agreeing to participate in the baseline
health examination was taken to indicate informed consent. Record linkage of national health
registers to the survey data has been approved by the register authorities.
Stroke subtype definitions
Stroke subtypes were initially classified according to Trial of Org 10172 in Acute Stroke Treatment
(TOAST) criteria (17). Among the cryptogenic cases (TOAST 5), we further classified those with
ESUS according to the recently proposed criteria as non-lacunar stroke detected by CT or MRI;
absence of extracranial or intracranial atherosclerosis causing 50% luminal stenosis in arteries
supplying the ischemic area; absence of a major-risk cardioembolic source of embolism; and
absence of any other specific cause of index stroke (10). In our study, AF was systematically
searched either with 24-48-hour Holter ambulatory ECG monitoring, repeated ECGs during
hospitalization, or continuous ECG-monitoring in emergency unit or acute stroke unit. At least
transthoracic echocardiography was performed for all stroke patients in the ESUS group. Arterial
imaging was done either by CTA, MRA, or ultrasound imaging. We classified patients with an
incomplete diagnostic work-up in the non-ESUS cryptogenic group, as we did with patients not
fulfilling the other ESUS criteria.
Cardioembolism was defined as the stroke being clinically embolic, and the source was atrial
fibrillation or flutter, dilated cardiomyopathy, recent myocardial infarction, congenital heart disease,
8infective endocarditis, mechanical aortic valve, congestive heart failure, thrombotic endocarditis, or
atrial myxoma (18).
ECG analysis
All ECG recordings of both patients and controls were registered as standard 12-lead ECGs with 50
mm/s speed and 0.1 mV/mm amplitude while the subjects rested in supine position. Parameters
analyzed manually from the ECGs (by authors J.Pi and A.E) were P-wave duration, PTF (negative
terminal P-wave deflection in lead V1 ≥ 0.1 mV and ≥ 40 ms duration, early positive part not
considered, Figure 1), biphasic P-waves in inferior leads and LVH by either Sokolow-Lyon or
Cornell Voltage duration criteria (1,19,20). First-degree interatrial block (IAB) was defined as P-
wave duration ≥110 ms and third-degree IAB as a P-wave duration of ≥110 ms and biphasic P-
waves in at least two inferior limb leads (21). P-waves were considered abnormal when either IAB
of first or third degree or PTF was present.
Statistical analysis
The strengths of association between markers of atrial abnormalities and IS occurrence were
estimated using conditional logistic regression. Odds ratios and 95 % confidence intervals were
calculated for the markers, and intervals not crossing the value 1.00 were considered significant.
Analyses were first performed in the entire population, adjusting for clinical variables satisfying
criteria for confounding. The models thus consisted of systolic blood pressure, diastolic blood
pressure, HDL cholesterol, obesity, diabetes, coronary artery disease and cigarette smoking, and an
ECG variable. Each ECG variable was tested in a separate model.  Since the confounding factors
varied from one subgroup to another, each subgroup analysis thus had a unique set of adjusted
variables (Table s2). Control group in the subgroup analyses consisted of only the corresponding
9controls for the cases in question. All analyses were performed on IBM SPSS 22.0 (Armonk, N.Y.,
USA).
Results
Descriptive data on clinical variables of patients and controls are shown in Table 1. Of the patients,
6.5% suffered their stroke due to large-artery atherosclerosis (LAA), 14.8% due to small-vessel
disease (SVD), 9.0% due to cardioembolism (CE), 27.3% due to rare causes, 28.6% due to ESUS,
and 13.8% were cryptogenic other than ESUS. Stroke patients had their ECG obtained at a median
of 2 days (interquartile range 1-3 days) after stroke.
Stroke patients had a median CHADS2 score of 2 points (interquartile range 2-3) and a median
CHA2DS2-VASc score of 3 (interquartile range 2-4). The cardioembolism patients had a median
CHADS2 of 3 (interquartile range 2-4) and a median CHA2DS2-VASc score of 4 (interquartile
range 3-5).
Of the cardioembolism patients, two used warfarin prior to stroke, and seven were on antiplatelet
therapy. Nine cardioembolism patients were known to suffer from AF, and more detailed data on
cardioembolic sources are found in Table s3.
Association of ECG findings, clinical parameters and stroke in the entire population
Correlations between clinical variables and ECG parameters are shown in supplementary Table s4.
The prevalence of different ECG abnormalities in the controls and the etiological subgroups of
stroke patients are displayed in Table 2. After multivariate adjustment, the parameters
independently associated with stroke of any kind were first-degree IAB, PTF in combination with
LVH, abnormal P-waves, and abnormal P-waves in combination with LVH (Table 3).
10
Association of ECG findings according to stroke subtype
Since the third-degree IAB was too scarce for analysis in the subgroups, third-degree IAB and its
combination with LVH were not included in the subgroup analyses. LVH, first-degree IAB, first-
degree IAB combined with LVH, PTF, PTF combined with LVH, abnormal P-wave and abnormal
P-wave combined with LVH were independently associated with cardioembolism stroke subtype
(Table 4). LVH was associated with SVD, although only in the univariate analysis (Table s5). First-
degree IAB and abnormal P-wave were associated with non-ESUS cryptogenic stroke subtype.
(Supplementary Table s2).
Discussion
Our main result is that in our cohorts of young stroke patients and their age- and sex-matched
controls, LVH and several abnormal P-wave parameters were independently associated with
cardioembolic stroke subtype, while the only other subgroup associated with P-wave abnormalities
was the non-ESUS cryptogenic group. We also found LVH associated with SVD.
In recent years, the role of atrial fibrillation as a risk factor for cardioembolic stroke has expanded
from arrhythmia, causing stasis and thrombus formation in the left atrial appendage, to a marker of
fibrotic atrial cardiopathy. In fibrotic atrial cardiopathy, the fibrosis disrupts atrial electrical
conduction properties, predisposing to re-entry and proliferation of ectopic foci promoting atrial
fibrillation, whereas inflammation, endothelial dysfunction, and atrial hypocontractility promote
thrombus formation (6,22). P-wave duration is a crude marker of atrial electrical conduction
properties. PTF serves relatively well as a marker of left atrial dilatation, but it can be caused also
by impaired interatrial conduction and especially of elevated left atrial pressure (23,24). The
subacute setting of stroke is probably not the cause of PTF per se, and the patients were already in
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hospital treatment and therefore possible cases of cardiac decompensation were probably already
treated. Both prolonged P-wave duration and PTF have been associated with increased risk of
developing AF (25,26). Thus, the large prevalence of these abnormalities especially in stroke
patients is not surprising. It was recently shown that both PTF and advanced (third-degree) IAB
were associated with IS in large multiracial general population cohorts even after accounting for the
presence of atrial fibrillation (2,3). We also found that PTF and first-degree IAB were associated
with cardioembolic stroke, although our cases with third-degree IAB were too few for analyses.
This is an interesting and novel finding, as in young stroke patients, the causes of cardioembolism
are markedly more diverse than in older population. However, the presence of P-wave
abnormalities in an ECG of a young stroke patient should encourage the clinician to think of the
possibility of cardioembolism.
Of special interest would be, whether the ESUS or cryptogenic stroke subgroups would share
similar ECG abnormalities as the cardioembolism subgroup, and thus suggest a common
pathogenesis of stroke in these groups. A positive, inconclusive trend of PTF associated with the
risk of cryptogenic stroke was found in a case-control study of markedly older stroke patients,
although in general, PTF was associated with stroke (27). Another study found PTF to be associated
with non-lacunar strokes independently of AF (28). We found novel associations between first-
degree IAB and P-wave abnormalities with non-ESUS cryptogenic stroke, although weaker than
with cardioembolism.  In older patients, ECG markers of left atrial abnormality have been found to
be independent risk markers for IS even when considering echocardiographic parameters (29). The
theory of fibrotic atrial cardiopathy, as described earlier, is receiving more evidence, although the
mechanisms of cryptogenic strokes and ESUS may be different in young and old patients.
Both PTF and increased P wave duration are markers of atrial pathology; however, the prevalence
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of these markers is relatively high also among subjects free of apparent cardiac disease (12,26).
Thus, we assumed that using a combination of markers of atrial pathology and LVH would be a
more specific indicator of significant cardiac pathology, and thus a stronger risk marker. Based on
an earlier study, there might be a synergy in stroke risk between atrial ECG abnormalities and LVH
on ECG. In that study, including 55-60-year-old patients, it was found that an abnormal P-wave
increased the risk of stroke in a cohort of patients with LVH (30). Pathophysiologically atrial
abnormality on ECG, indicating left atrial pressure overload, could also be viewed as a marker of
systolic or diastolic dysfunction of the left ventricle, reflecting more severe heart disease than
isolated LVH alone (31). We found LVH with P-wave abnormalities associated with cardioembolic
stroke, as did LVH per se LVH was also associated with SVD in our univariate analysis (Table s5).
SVD is strongly associated with diabetes, and the finding could reflect a recent finding of type 2
diabetes being a risk factor for LVH, independent of hypertension (32). We also found diabetes
significantly correlating with LVH, and the higher amount of diabetes type 2 in the SVD subgroup
could explain LVH being associated with SVD (Table s4). Although patients with small-vessel
disease as their etiology had the highest frequency for arterial hypertension (85%), PTF was
overrepresented only in the cardioembolism group but not in SVD group, indicating PTF is a sign
of major changes in cardiac structure and electric function rather than early cardiac stress due to
hypertension.
Our study has strengths and limitations. The main limitation is the time difference in enrollment of
the case- and control cohorts. Since blood pressure levels might be different between the time
periods, namely higher in general population during the control population's era, the prevalence of
LVH could be overestimated in our control population. Other limitations include the relatively
small numbers of patients in etiologic subgroups, the low prevalence of certain studied ECG
markers, and the lack of AF data in control subjects. The confidence intervals in some subgroup
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analyses apart from cardioembolism were broad, and type 2 errors cannot be ruled out. Strengths
include the case- and control populations being from the same region and a large number of young
patients with IS in the stroke cohort. The lack of echocardiography data can also be considered a
limitation, although there is also value in knowing what ECG can tell regardless of
echocardiographic findings.
Conclusions
We found that PTF and first-degree IAB were associated with IS in young adults. With further
analysis in subgroups, we observed that this association applied only to cardioembolic and non-
ESUS cryptogenic subtype.
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Figure and table legends
Figure 1. Sample cardiac cycles of studied ECG parameters. Panel a) first-degree IAB (P-wave
duration >110 ms, without positive-negative morphology in inferior leads), b) third-degree IAB (P-
wave duration >110 ms, positive-negative morphology can be seen in leads II, aVF and III), c) PTF
(negative terminal part of P-wave in V1 >40 ms duration and deeper than -1.0 mm).
Table 1. Demographics, blood pressure, cholesterol and comorbidities in cases and controls.
Numbers are median (interquartile range) for continuous parameters and n (%) for dichotomous
parameters.
Table 2. Prevalence of different ECG abnormalities in stroke etiologic subgroups and controls.
Numbers are n (%).
Table 3. ECG abnormality differences between cases (N=567) and controls (N=1033). Conditional
logistic regression adjusted for systolic blood pressure, diastolic blood pressure, HDL cholesterol,
obesity, diabetes, coronary artery disease and cigarette smoking. In P-wave parameter-LVH
combinations, the reference group is those having neither abnormality.
Table 4. Conditional logistic regression analysis on the ECG abnormalities associated with
cardioembolic stroke subtype (N=51). Model adjusted for diastolic blood pressure and HDL
cholesterol. As controls for the cardioembolism patients, only the defined as the control population
for the cardioembolism patients are used (N=87).
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Table 1.
Parameter Cases
N= 567
Controls
N= 1033
Age 44 (37-47) 43 (38-47)
Systolic blood pressure, mmHg 140 (125-156) 134 (125-145)
Diastolic blood pressure, mmHg 84 (75-94) 88 (81-95)
HDL cholesterol, mmol/L 1.3 (1.1-1.6) 1.7 (1.4-1.9)
Obesity 62 (11) 115 (11)
Diabetes 64 (13) 11 (1)
Coronary artery disease 27 (5) 14 (1)
Cigarette smoking 256 (45) 329 (32)
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Table 2.
ECG abnormality LAA
N=37
CE
N=51
SVD
N=84
Rare causes
N=155
ESUS
N=162
Non-ESUS
Cryptogenic
N=78
Controls
N=1033
LVH regardless of
other ECG findings
13 (35.1) 24
(47.1)
23 (27.4) 28 (18.1) 24
(14.8)
11 (14.1) 183 (17.7)
First-degree IAB 10 (27.0) 30
(58.8)
30 (35.7) 46 (29.7) 49
(30.2)
23 (29.5) 296 (28.7)
First-degree IAB
and LVH
7 (18.9) 13
(25.5)
9 (10.7) 9 (5.8) 9 (5.6) 6 (7.7) 62 (6.0)
P-terminal force 1 (2.7) 15
(29.4)
1 (1.2) 4 (2.6) 0 1 (1.3) 31 (3.0)
P-terminal force and
LVH
1 (2.7) 7
(13.7)
0 4 (2.6) 0 1 (1.3) 7 (0.7)
Abnormal P-wave 13 (35.1) 34
(66.7)
33 (39.3) 51 (32.9) 56
(34.6)
26 (33.3) 342 (33.1)
Abnormal P-wave
and LVH
8 (21.6) 15
(29.4)
10 (11.9) 12 (7.7) 10 (6.2) 7 (9.0) 71 (6.9)
Third-degree IAB 3 (8.1) 1
(2.0)
2 (2.4) 3 (1.9) 7 (4.3) 3 (3.8) 29 (2.8)
Third-degree IAB
and LVH
2 (5.4) 0 1 (1.2) 1 (0.6) 1 (0.6) 1 (1.3) 7 (0.7)
LAA = large-artery atherosclerosis, SVD = small-vessel disease, CE = cardioembolism, ESUS =
embolic stroke of undetermined source.
LVH = left ventricular hypertrophy, IAB = interatrial block.
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Table 3.
ECG abnormality Odds ratio (95% confidence interval)
LVH regardless of other ECG findings 1.31 (0.91-1.87)
First-degree IAB 1.57 (1.16-2.13)
First-degree IAB and LVH 1.81 (0.06-3.09)
P-terminal force 1.14 (0.50-2.59)
P-terminal force and LVH 6.83 (1.65-28.31)
Abnormal P-wave 1.52 (1.28-2.05)
Abnormal P-wave and LVH 1.80 (1.09-2.96)
Third-degree IAB 1.02 (0.47-2.20)
Third-degree IAB and LVH 0.68 (0.16-2.84)
LVH = left ventricular hypertrophy, IAB = interatrial block.
Table 4.
ECG abnormality Odds ratio (95% confidence
interval)
LVH regardless of other ECG findings 3.01 (1.01-8.95)
First-degree IAB 5.40 (1.61-18.13)
First-degree IAB and LVH 5.18 (1.16-23.18)
P-terminal force 31.92 (3.27-311.16)
P-terminal force and LVH 46.96 (2.65-832.92)
Abnormal P-wave 4.96 (1.53-16.05)
Abnormal P-wave and LVH 5.63 (1.37-23.23)
LVH = left ventricular hypertrophy, IAB = interatrial block.
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Table s1. Definitions of the clinical parameters.
Parameter Cases Controls
Systolic blood pressure Systolic blood pressure on admission or 24 h after
admission; mean of both when available
Mean of systolic blood pressure measured after 5 minutes of rest
and 1½ minutes after the first measurement
Diastolic blood pressure Diastolic blood pressure on admission or 24 h after
admission; mean of both when available
Mean of diastolic blood pressure measured after 5 minutes of
rest and 1½ minutes after the first measurement
HDL cholesterol Blood sample 24-72 hours after admission Blood sample at health examination*
Obesity Body mass index ≥30 kg/m2 Body mass index ≥30 kg/m2
Diabetes Fasting plasma glucose ≥7.0 mmol/l (126 mg/dL) or plasma
glucose after ingestion of 75 g oral glucose ≥11.1 mmol/l
(200 mg/dL), with or without insulin dependence (WHO
criteria)
Diagnosis of either type 1 or type 2 diabetes at the time of
evaluation; only fasting glucose was measured from all
participants
Coronary artery disease Coronary artery disease diagnosed before the stroke;
previous myocardial infarction, or a positive result in
diagnostic methods such as perfusion imaging, coronary
angiography or exercise ECG
Diagnosis of coronary artery disease at the time of evaluation;
previous myocardial infarction, or a positive result in diagnostic
methods such as perfusion imaging, coronary angiography or
exercise ECG
Cigarette smoking Smoking at least one cigarette per day within one year
before the stroke
Smoking cigars, pipe or at least one cigarette every or almost
every day within one year before the comprehensive clinical
examination including ECG
*All cholesterol measurements of control subjects were performed using the Lieberman-Buchard method.1 HDL was measured from the supernatant
after precipitation with Mg++/dextran sulphate.2,3
Table s2. ECG abnormality differences between controls and cases of different stroke etiologies (for CE, see Table 4). Each patient group was adjusted
for the parameters found associated with stroke in univariate analysis (P<0.10). LAA was adjusted for smoking, systolic blood pressure, diabetes and
HDL cholesterol. SVD was adjusted for smoking, systolic blood pressure, obesity, coronary artery disease and HDL cholesterol. Etiology of rare
causes was adjusted for systolic blood pressure, diastolic blood pressure, diabetes and HDL cholesterol. ESUS was adjusted for smoking, diastolic
blood pressure and HDL cholesterol. Cryptogenic stroke was adjusted for smoking, diastolic blood pressure, diabetes and HDL cholesterol. Numbers
are odds ratio in comparison to controls and 95 % confidence interval.
ECG abnormality LAA
N=37
SVD
N=84
Rare causes
N=155
ESUS
N=162
Non-ESUS
cryptogenic
N=78
LVH regardless of other ECG findings 0.49 (0.11-2.25) 1.66 (0.69-4.03) 1.30 (0.60-2.79) 1.12 (0.59-2.14) 1.33 (0.49-3.65)
First-degree IAB 1.56 (0.32-7.71) 1.06 (0.52-2.14) 1.76 (0.92-3.35) 1.36 (0.81-2.28) 3.83 (1.47-9.98)
First-degree IAB and LVH 2.05 (0.28-14.94) 0.74 (0.23-2.41) 1.55 (0.44-5.51) 1.56 (0.58-4.17) 2.70 (0.55-13.23)
P-terminal force 0.02 (0.00-20.69) 0.24 (0.02-3.19) 0.46 (0.05-3.90) - 0.28 (0.01-15.47)
P-terminal force and LVH 0.02 (0.00-20.54) - 2.61 (0.16-42.50) - 2.10 (0.01-478.26)
Abnormal P-wave 0.57 (0.11-2.85) 0.88 (0.43-1.78) 1.64 (0.86-3.11) 1.34 (0.80-2.26) 2.84 (1.23-6.56)
Abnormal P-wave and LVH 1.78 (0.25-12.90) 1.03 (0.32-3.29) 1.16 (0.34-3.89) 1.50 (0.60-3.80) 2.28 (0.57-9.20)
LAA = large-artery atherosclerosis, SVD = small-vessel disease, CE = cardioembolism, ESUS = embolic stroke of undetermined source.
LVH = left ventricular hypertrophy, IAB = interatrial block.
Table s3. Cardiac diseases of patients with cardioembolic stroke.
Cardiac disease Number of patients (%)
Cardiomyopathy 18 (35)
Atrial fibrillation of flutter 9 (18)
Myocardial infarction/left ventricular thrombus 7 (14)
Endocarditis 5 (10)
Congenital cardiac malformations 4 (8)
Congestive heart failure 3 (6)
Mechanical valve 3 (6)
Myxoma 2 (4)
Table s4. Pearson correlations between clinical parameters and ECG findings. P-values >0.05 are considered not significant (n.s.). The CHADS2 and
CHA2DS2-VASc scores are calculated from stroke patients data only, since vascular disease and congestive heart failure were not well documented in
control subjects.
LVH 1° IAB 1°IAB &
LVH
PTF PTF &
LVH
Abnormal P-
wave
Abnormal P-
wave & LVH
3°IAB 3°IAB &
LVH
Sex* -0.21 -0.15 -0.12 n.s. -0.06 -0.18 -0.14 -0.07 n.s.
Age n.s. 0.14 0.06 0.06 n.s. 0.17 0.08 0.06 0.06
Smoking n.s. n.s. -0.05 n.s. n.s. n.s. -0.06 n.s. -0.05
Systolic blood pressure 0.23 0.12 0.17 0.08 0.12 0.15 0.20 0.08 0.13
Diastolic blood pressure 0.19 0.16 0.16 0.06 0.10 0.18 0.18 0.10 0.11
Obesity -0.05 0.07 n.s. 0.06 n.s. 0.12 n.s. 0.10 n.s.
Coronary artery disease n.s. n.s. 0.06 0.10 0.05 0.07 0.08 0.09 0.07
Diabetes 0.06 n.s. 0.05 0.09 0.11 n.s. 0.07 n.s. 0.08
HDL level -0.05 -0.08 -0.07 n.s. n.s. -0.12 -0.08 -0.11 n.s.
CHADS2 score 0.26 0.12 0.20 0.27 0.24 0.17 0.25 0.08 0.15
CHA2DS2-VASc score 0.18 n.s. 0.13 0.28 0.22 n.s. 0.17 n.s. n.s.
*Positive correlation indicates correlation with female gender
LVH = left ventricular hypertrophy, IAB = interatrial block, PTF = P-terminal force.
Table s5. Univariate conditional logistic regression analysis on the ECG abnormalities associated with stroke subtypes. Numbers are odds ratio in
comparison to controls and 95 % confidence interval.
ECG abnormality LAA
N=37
CE
N=51
SVD
N=84
Rare causes
N=155
ESUS
N=162
Non-ESUS
cryptogenic
N=78
LVH regardless of other ECG findings 1.75 (0.69-4.49) 2.79 (1.22-6,34) 2.13 (1.10-4.14) 1.21 (0.68-2.16) 0.71 (0.41-1.25) 0.79 (0.36-1.74)
First-degree IAB 0.85 (0.38-1.89) 3.97 (1.74-9.05) 1.01 (0.59-1.74) 1.28 (0.79-2.05) 1.31 (0.83-2.05) 1.23 (0.64-2.35)
First-degree IAB and LVH 2.22 (0.74-6.63) 4.21 (1.47-12.07) 1.67 (0.65-4.30) 1.56 (0.63-3.90) 0.97 (0.43-2.20) 1.00 (0.32-3.17)
P-terminal force 0.59 (0.05-7.43) 12.89 (2.93-56.74) 0.40 (0.05-3.42) 1.16 (0.32-4.22) - 0.35 (0.04-3.36)
P-terminal force and LVH 1.00 (0.05-18.91) 12.15 (1.48-99.53) - 4.00 (0.73-21.84) - 2.00 (0.13-31.98)
Abnormal P-wave 0.88 (0.40-1.91) 4.83 (2.06-11.37) 1.04 (0.61-1.77) 1.25 (0.79-1.98) 1.22 (0.79-1.89) 1.12 (0.61-2.06)
Abnormal P-wave and LVH 2.34 (0.80-6.85) 4.99 (1,79-13.98) 1.89 (0.75-4.73) 1.60 (0.71-3.63) 0.92 (0.42-2.02) 1.00 (0.35-2.83)
LAA = large-artery atherosclerosis, SVD = small-vessel disease, CE = cardioembolism, ESUS = embolic stroke of undetermined source.
LVH = left ventricular hypertrophy, IAB = interatrial block.
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